Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
Stocks · News reference
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stocks bucked the selloff.
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
Arrowhead Pharmaceuticals shares are trading lower. The company announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, RNAi therapeutic dimer for the treatment of mixed hyperlipidemia.